1,25-dihydroxyvitamin D3 as well as its analogue OCT lower blood calcium through inhibition of bone resorption in hypercalcemic rats with continuous parathyroid hormone-related peptide infusion

Journal of Bone and Mineral Research

Volumn 15, Issue 1, 2000, Pages 175-181

  Endo, Ko Ichi ^a   Katsumata, Kyoko ^a   Hirata, Michinori ^a   Masaki, Toshimi ^a   Kubodera, Noboru ^a   Nakamura, Toshitaka ^b   Ikeda, Kyoji ^c   Ogata, Etsuro ^d  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^d CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

Active vitamin D; Bone resorption; Hypercalcemia; Parathyroid hormone related peptide

Indexed keywords

CALCITRIOL; CALCITRIOL DERIVATIVE; CALCIUM; PARATHYROID HORMONE RELATED PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE METABOLISM; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM METABOLISM; CONTROLLED STUDY; HYPERCALCEMIA; MALE; NONHUMAN; OSTEOLYSIS; OSTEOPOROSIS; RAT; URINARY EXCRETION;

EID: 0033962847     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.2000.15.1.175     Document Type: Article

References (25)

1. Broadus AE 1992 Identification of the parathyroid hormone-related peptide. In: Halloran BP, Nissenson RA (eds.) Parathyroid Hormone-Related Protein: Normal Physiology and Its Role in Cancer. CRC Press, Boca Raton, FL, pp. 1-23.
2. Martin TJ, Moseley JM, Gillespie MT 1991 Parathyroid hormone-related protein: biochemistry and molecular biology. Crit Rev Biochem Molec Biol 26:377-395.
3. Ikeda K, Lu C. Weir EC, Mangin M, Broadus AE 1989 Transcriptional regulation of the parathyroid hormone-related peptide gene by glucocorticoids and vitamin D in a human C-cell line. J Biol Chem 264:15743-15746.
4. Inoue D, Matsumoto T, Ogata E, Ikeda K 1993 22-Oxacalcitriol, a noncalcemic analogue of calcitriol, suppresses both cell proliferation and parathyroid hormone-related peptide gene expression in human T cell lymphotrophic virus, type I-infected t cells. J Biol Chem 268:16730-16736.
5. Endo K, Ichikawa F, Uchiyama Y, Katsumata K, Ohkawa H, Kumaki K, Ogata E, Ikeda K 1994 Evidence for the uptake of a vitamin D analogue (OCT) by a human carcinoma and its effect of suppressing the transcription of parathyroid hormone-related peptide gene in vivo. J Biol Chem 269:32693-32699.
6. Haq M, Kremer R, Goltzman D, Rabbani SA 1993 A vitamin D analogue (EB 1089) inhibits parathyroid hormone-related peptide production and prevents the development of malignancy-associated hypercalcemia in vivo. J Clin Invest 91:2416-2422.
7. Endo K, Katsumata K, Iguchi H, Kubodera N, Teramoto T, Ikeda K, Fujita T, Ogata E 1998 Effect of combination treatment with a vitamin D analog (OCT) and a bisphosphosphonate (AHPrBP) in a nude mouse model of cancer-associated hypercalcemia. J Bone Miner Res 13:1378-1383.
8. 3 analogues. Chem Pharmacol Bull 34:4410-4413.
9. Fujimoto S, Kubo T, Tanaka H, Miura M, Seino Y 1995 Urinary pyridinoline and deoxypyridinoline in healthy children and in children with growth hormone deficiency. J Clin Endocrinol Metab 80:1922-1928.
10. Tanaka Y, Nakamura T, Nishida S, Suzuki K, Takeda S, Sato K, Nishii Y 1996 Effects of a synthetic vitamin D analog, ED-71, on bone dynamics and strength in cancellous and cortical bone in prednisolone-treated rats. J Bone Miner Res 11:325-336.
11. Parfitt AM. Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res 2:595-610.
12. Harinck BIJ, Bijvoet OLM, Plantingh EST, Body J, Elte WF, Sleeboom P, Wildiers M, Neijt P 1987 Role of bone and kidney in tumor-induced hypercalcemia and its treatment with bisphosphonate and sodium chloride. Am J Med 82:1133-1142.
13. 3 in the osteoblast-like ROS 17/2.8 cells. Am J Physiol 270:E654-E660.
14. Kumar R 1997 Vitamin D and the kidney. In: Feldman D, Glorieux FH, Pike JW (eds.) Vitamin D. Academic Press, San Diego, CA, pp. 275-292.
15. Insogna KL, Stewart AF, Vignery AMC, Weir EC, Namnum PA, Baron RE, Kirkwood JM, Deftos LM, Broadus AE 1984 Biochemical and histomorphometric characterization of a rat model for humoral hypercalcemia of malignancy. Endocrinology 114:888-896.
16. Stewart AF, Horst R, Deftos LJ, Cadman EC, Lang R, Broadus AE 1980 Biochemical evaluation of patients with cancer-associated hypercalcemia. Evidence for humoral and nonhumoral groups. N Engl J Med 303:1377-1383.
17. Dusso AS, Negrea L, Finch J, Kamimura S, Lopez-Hilker S, Mori T, Nishii Y, Brown A, Slatopolsky E 1992 The effect of 22-oxacalcitriol on serum calcitriol. Endocrinology 130:3129-3134.
18. Reichel H, Koeffler HP, Norman AW 1989 The role of the vitamin D endocrine system in the health and disease. N Engl J Med 320:980-991.
19. Eastell R, Riggs BL 1997 Vitamin D and osteoporosis. In: Feldman D, Glorieux FH, Pike JW (eds.) Vitamin D. Academic Press, San Diego, CA, pp. 695-711.
20. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K, Ogata E 1999 The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcif Tissue Int 65:311-316.
21. Raisz LG, Trummel CL, Holick MF, DeLuca HF 1972 1,25-Dihydroxycholecalciferol: A potent stimulator of bone resorption in tissue culture. Science 175:768-769.
22. Suda T, Takahashi N, Martin TJ 1992 Modulation of osteoclast differentiation. Endocr Rev 13:66-80.
23. 3 on bone of thyroparathyroidectomzed rats fed on a low-calcium diet. Am J Pathol 92:459-465.
24. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T, Elliot R, Colombero A, Scully GES, Hsu H, Sullivan J, Hawkins N, Davy E, Capparelli C, Eli A, Qian YX, Kaufman S, Sarosi I, Shalhoub V, Senaldi G, Guo J, Delaney J, Boyle WJ 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165-176.
25. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinosaki M, Mochizuki S, Tomoyasu A, Yano K, Goto M, Murakami A, Tsuda E, Morinaga T, Higashio K, Udagawa N, Takahashi N, Suda T 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci USA 95:3597-3602.